Correction: Alfaro-Arnedo et al. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines 2021, 9, 912

In the original article [1], there was a mistake in Figure 4 as published. We made a mistake when choosing the representative image for the second panel in Figure 4C (corresponding to the “HDM +Vehicle” treatment). The corrected Figure 4 appears below.

Figure 4.

Therapeutic inhibition of IGF1R attenuates AHR and normalizes pulmonary surfactant expression upon HDM-induced allergy. (A) Quantification of lung resistance (LR) and dynamic compliance (Cdyn) to methacholine (MCh) evaluated by plethysmography (n = 4–8 mice per group) and (B) changes in lung tissue mRNA expression surfactant (Sftp) markers Sftpa1, b c, and d, normalized to 18S expression in HDM-challenged mice treated with NVP vs. controls (n = 5 mice per group). (C) Representative immunostains for SFTPC (green) (white arrowheads), and quantification of the number of SFTPC⁺ cells per unit area (mm²) in lung sections from HDM-challenged mice treated with NVP vs. controls (n = 5–10 mice per group; scale bar: 50 µm). Data are expressed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.05 (comparisons within the same group) (Mann–Whitney U test or Student’s t-test for comparing two groups and Kruskal–Wallis test or ANOVA multiple comparison test for grouped or multivariate analysis).

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.